

MYRIAD GENETICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended

	<u>(unaudited)</u> Sept. 30, 2000	<u>(unaudited)</u> Sept. 30, 1999
REVENUES:		
Research revenue	\$7,769,251	\$5,247,645
Molecular diagnostic revenue	3,050,009	1,614,286
Total revenues	10,819,260	6,861,931
COSTS AND EXPENSES:		
Molecular diagnostic cost of revenue	1,305,362	802,931
Research and development expense	8,790,797	5,786,801
Selling, general and administrative expense	3,943,390	3,021,986
Total costs and expenses	14,039,549	9,611,718
Operating loss	(3,220,289)	(2,749,787)
Other income (expense):		
Interest income	1,398,293	573,789
Other	(248,465)	(15,094)
	1,149,828	558,695
Net loss	(\$2,070,461)	(\$2,191,092)
Basic and diluted loss per share	(\$0.09)	(\$0.12)
Basic and diluted weighted average shares outstanding	22,032,596	18,865,474

SELECTED BALANCE SHEET DATA

	<u>Sept. 30, 2000</u>	<u>June 30, 2000</u>
Cash and investments	\$104,548,476	\$88,655,844
Total assets	\$122,227,963	\$106,375,305
Shareholders' equity	\$98,198,628	\$77,706,647